ALKS 33-BUP + ALKS 33 + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cocaine Abuse
Conditions
Cocaine Abuse
Trial Timeline
Aug 1, 2011 → Feb 1, 2012
NCT ID
NCT01366001About ALKS 33-BUP + ALKS 33 + Placebo
ALKS 33-BUP + ALKS 33 + Placebo is a phase 1 stage product being developed by Alkermes for Cocaine Abuse. The current trial status is completed. This product is registered under clinical trial identifier NCT01366001. Target conditions include Cocaine Abuse.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01366001 | Phase 1 | Completed |
Competing Products
13 competing products in Cocaine Abuse
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Topiramate + Cognitive Behavioral Therapy + Placebo + Cognitive Behavioral Therapy | Johnson & Johnson | Phase 3 | 77 |
| Topiramate | Johnson & Johnson | Phase 2 | 52 |
| quetiapine | AstraZeneca | Approved | 85 |
| quetiapine fumarate + Matched Placebo | AstraZeneca | Pre-clinical | 23 |
| AFQ056 + Placebo | Novartis | Phase 1 | 33 |
| AFQ056 + Placebo | Novartis | Phase 2 | 52 |
| VIVITROL (Naltrexone extended-release injectable suspension) + Placebo | Alkermes | Phase 2 | 49 |
| vigabatrin + placebo | Catalyst Pharmaceuticals | Phase 2 | 47 |
| Vigabatrin + Matching Placebo | Catalyst Pharmaceuticals | Phase 2/3 | 60 |
| Vigabatrin + Placebo | Catalyst Pharmaceuticals | Phase 2 | 47 |
| CPP-115 + Placebo | Catalyst Pharmaceuticals | Phase 1 | 28 |
| TNX-1300 | Tonix Pharmaceuticals | Phase 2 | 44 |
| TNX-1300 (Injection) + Placebo (Injection) | Tonix Pharmaceuticals | Phase 2 | 44 |